Glucagon-like peptide-1 (GLP-1) Biological Role in Patients of Type 2 Diabetes and Metabolic Syndrome
Type2 diabetes is estimated to affect 380 million people worldwide in 2025. Patients of this disease are at increased risk of cardiovascular diseases (CVD).The CVD risk is greater when diabetic patients have metabolic syndrome. Thus, the management of metabolic syndrome and CVD is crucial for diabetic patient’s life progress. GLP-1 has positive biological influences on glucose metabolism control by inhibiting glucagon secretion, enhancing insulin secretion and protecting the effects of cells. GLP-1 was also found to have other positive influences including weight loss, appetite sensation and food intake. These are important factors in metabolic disturbances control and CVD management. The paper reviewed several studies regarding the GLP-1 positive concerns. In conclusion, the paper supports the modern proposal of GLP-1 RAs as a first line therapy in initially diagnosed type 2 diabetes patients.
- Yoo, S., Yang, E.J., Lee, S.A. and Koh, G. Post meal increment in intact glucagon-like peptide 1 level, but not intact glucose-dependent insulinotropic polypeptide levels, is inversely associated with metabolic syndrome in patients with type 2 diabetes. Endocrine Res., 2018, 43, 47-54.
- Bodnaruc, A. M., Prud’homme, D., Blanchet, R. and Giroux, I. Nutritional modulation of endogenous glucagon-like peptide-1 secretion: a review. Nutr. Metabol., 2016, 13, 92.
- Dar, S., Tahrani, A.A. and Piya, M.K. The role of GLP 1 receptor agonists as weight loss agents in patients with and without type 2 diabetes. Practical Diab., 2015, 32, 297.
- Htike, Z.Z., Zaccardi, F., Papamargaritis, D., Webb, D.R., Khunti, K. and Davies, M.J. Efficacy and safety of glucagon like peptide 1 receptor agonists in type 2 diabetes: A systematic review and mixed treatment comparison analysis. Diabetes, Obesity and Metabol., 2017, 19, 524-536.
- AL-Domi, H. and Mahmud, I. Anti-obesity effect of peripheral exendin-4 and/or exercise in high-fat diet-induced obese C57bl/6 mice. Pak. J. Nutr., 2016, 15, 379.
- Abdul-Ghani, M. and DeFronzo, R.A. Is it time to change the type 2 diabetes treatment paradigm? Yes! GLP-1 RAs should replace Metformin in the type 2 diabetes algorithm. Diabetes care, 2017, 40, 1121-1127.
- Nauck, M.A. and Meier, J.J. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. The Lancet Diab. Endocrinol., 2016, 4, 525-536.
- Holst, J.J., Gribble, F., Horowitz, M. and Rayner, C.K. Roles of the gut in glucose homeostasis. Diabetes Care, 2016, 39, 884-892.
- Campbell, J.E. and Drucker, D.J. Pharmacology, physiology and mechanisms of incretin hormone action. Cell Metabol., 2013, 17, 819-837.
Abstract Views: 14
PDF Views: 0